Lenox Wealth Management Inc. Buys 237 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Lenox Wealth Management Inc. lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,463 shares of the biopharmaceutical company’s stock after purchasing an additional 237 shares during the quarter. Lenox Wealth Management Inc.’s holdings in Gilead Sciences were worth $599,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in GILD. Advisors Preferred LLC acquired a new position in Gilead Sciences during the second quarter worth $26,000. First Financial Corp IN increased its holdings in shares of Gilead Sciences by 286.4% in the third quarter. First Financial Corp IN now owns 541 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 401 shares during the last quarter. Legacy Advisors LLC acquired a new position in shares of Gilead Sciences in the second quarter valued at $37,000. Venturi Wealth Management LLC acquired a new position in shares of Gilead Sciences in the third quarter valued at $40,000. Finally, Evolution Wealth Advisors LLC acquired a new position in shares of Gilead Sciences in the second quarter valued at $46,000. 79.91% of the stock is currently owned by institutional investors and hedge funds.

GILD has been the topic of several research reports. BMO Capital Markets decreased their price objective on shares of Gilead Sciences from $82.00 to $81.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Oppenheimer decreased their price objective on shares of Gilead Sciences from $85.00 to $80.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Jefferies Financial Group set a $95.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a report on Monday, July 15th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a report on Monday, July 15th. Finally, Robert W. Baird set a $76.00 price objective on shares of Gilead Sciences and gave the company a “hold” rating in a report on Friday, October 25th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, fourteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. Gilead Sciences currently has a consensus rating of “Buy” and a consensus price target of $79.27.

Shares of GILD stock traded up $1.42 on Friday, hitting $65.38. The company’s stock had a trading volume of 4,953,000 shares, compared to its average volume of 6,639,518. The stock’s 50 day moving average is $64.15 and its 200-day moving average is $65.25. Gilead Sciences, Inc. has a fifty-two week low of $60.32 and a fifty-two week high of $72.90. The company has a debt-to-equity ratio of 1.13, a quick ratio of 2.96 and a current ratio of 3.06. The company has a market capitalization of $82.81 billion, a PE ratio of 10.63, a PEG ratio of 3.47 and a beta of 1.09.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 24th. The biopharmaceutical company reported $1.75 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.74 by $0.01. Gilead Sciences had a return on equity of 37.50% and a net margin of 12.04%. The company had revenue of $5.60 billion during the quarter, compared to the consensus estimate of $5.61 billion. During the same quarter in the prior year, the firm posted $1.84 earnings per share. The firm’s revenue was up .1% compared to the same quarter last year. On average, research analysts forecast that Gilead Sciences, Inc. will post 6.66 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 3.85%. The ex-dividend date is Thursday, December 12th. Gilead Sciences’s dividend payout ratio is currently 40.98%.

In other Gilead Sciences news, EVP Brett A. Pletcher sold 5,677 shares of the stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $63.31, for a total transaction of $359,410.87. Following the completion of the sale, the executive vice president now owns 21,521 shares of the company’s stock, valued at approximately $1,362,494.51. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Brett A. Pletcher sold 608 shares of the stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $64.35, for a total transaction of $39,124.80. Following the sale, the executive vice president now directly owns 27,198 shares of the company’s stock, valued at approximately $1,750,191.30. The disclosure for this sale can be found here. Insiders sold 17,288 shares of company stock valued at $1,108,682 in the last ninety days. 0.20% of the stock is currently owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Recommended Story: Trade War

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.